Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr HIV/AIDS Rep. 2010 Feb;7(1):19-27. doi: 10.1007/s11904-009-0035-7.

Use of nonhuman primate models to develop mucosal AIDS vaccines.

Author information

  • 1Center for Comparative Medicine, California National Primate Research Center, University of California, Davis, One Shields Avenue, Davis, CA, 95616, USA. mgenesca@primate.ucdavis.edu

Abstract

The HIV vaccines tested in the halted Step efficacy trial and the modestly successful phase 3 RV144 trial were designed to elicit strong systemic immune responses; therefore, strategies to direct immune responses into mucosal sites should be tested in an effort to improve AIDS vaccine efficacy. However, as increased CD4(+) T-cell activation and recruitment to mucosal sites have the potential to enhance HIV transmission, mucosal immune responses to HIV vaccines should primarily consist of effector CD8(+) T cells and plasma cells. Controlling the level of mucosal T-cell activation may be a critical factor in developing an effective mucosal AIDS vaccine. Immunization routes and adjuvants that can boost antiviral immunity in mucosal surfaces offer a reasonable opportunity to improve AIDS vaccine efficacy. Nonhuman primate models offer the best system for preclinical evaluation of these approaches.

PMID:
20425054
[PubMed - indexed for MEDLINE]
PMCID:
PMC2824120
Free PMC Article

Images from this publication.See all images (1)Free text

Fig. 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk